Author:
Simpson K.,Parker J.,Plumer J.,Bloom S.
Publisher
Springer Berlin Heidelberg
Reference160 articles.
1. TM Pharma (2007) Results from a Phase I/II clinical study with the drug candidate Obinepitide for the treatment of obesity. Press release 28th Nov 2007.
http://www.7tm.com/News/News_Archive.aspx?M=News&PID=45&NewsID=9
2. TM Pharma (2011) TM30339. Metabolic disorders
http://www.7tm.com/R-D/Metabolic_Disorders/TM30339.aspx
3. Abbott CR, Small CJ, Kennedy AR, Neary NM, Sajedi A, Ghatei MA et al (2005a) Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 1043(1–2):139–144
4. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR et al (2005b) The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044(1):127–131
5. Acuna-Goycolea C, van den Pol AN (2005) Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J Neurosci 25(45):10510–10519
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献